Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is experiencing a short-term headwind due to a shift toward genome testing. However, the company's new outpatient genome coverage policy has the potential to increase their average selling price by $100. Additionally, the company's ongoing execution and investment, including a tripling of their sales force, should help capitalize on the expanding market for genetic testing, particularly in pediatrics and rare diseases. The recent acquisition of Fabric Genomics, a genomic interpretation software business, could also provide additional revenue streams and help expand GeneDx's customer base globally. Overall, GeneDx's focus on genomics and commitment to advancing precision medicine positions them well for long-term success.

Bears say

GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services with a focus on whole exome and genome sequencing. However, its recent financial results have missed expectations due to headwinds from mix and softness in the non-core business. While the company has the potential to transform healthcare and drive improved outcomes with its genomic intelligence, there are risks associated with pricing and competition in its core businesses, as well as regulatory and operational execution risks. Additionally, GeneDx's expansion into new markets, such as pediatricians and newborn screening, may take time to convert early adopters and could present further operational risks.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of Jun 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $74.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $74.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.